Skip to content

A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects.

A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects. - Drug interaction study between Midazolam and Anchu-san.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007982
Enrollment
6
Registered
2012-05-25
Start date
2012-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese healthy male

Interventions

Midazolam single oral administration Midazolam single oral administration after 6 days Anchu-san (7.5g/day) dose

Sponsors

Showa University School of Medicine Department of Clinical Pharmacology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Age: 20 - 45 years old at the time of informed consent 2)Sex: male 3) Subjects are competent to consent, keep the rules of the study and are able to report self condition. 4) Subjects who are judged eligible by the investigator in several series of medical check conducted prior to study.

Exclusion criteria

Exclusion criteria: 1) Subjects who have an inappropriate clinical history for efficacy and safety assessment in the study (such as drug abuse, alcoholism, and the disease of heart, liver, kidney, lungs, eye, blood etc) and who is taking any drugs (including health supplements). 2) Any history for drug allergy 3) Subjects who are taking in too much alcohol (those who cannot maintain the abstains from alcohol during study period) 4) Subjects within three months after the participation to other clinical trials 5) Subjects who are inadequate for enrollment judged by the investigator.

Design outcomes

Primary

MeasureTime frame
The pharmacokinetic parameters of midazolam in serum (AUC 0-10, Cmax, t1/2, tmax).

Secondary

MeasureTime frame
The sedative action after midazolam oral administration: VAS Safety assessment (pulse oximeter, vital measurement, adverse event)

Countries

Japan

Contacts

Public ContactHirokazu Toshima MD

Showa University School of Medicine Department of Clinical Pharmacology

showa_northern@yahoo.co.jp03-3784-8128

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026